BofA analyst Tim Anderson lowered the firm’s price target on Apogee Therapeutics (APGE) to $78 from $80 and keeps a Buy rating on the shares after the company reported FY24 financial results and released interim Phase 1 results for APG990 in healthy volunteers. The firm’s target reflects updated cash and share count estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics initiated with a Buy at Citi
- Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments
- Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position
- Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments
- Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress